 DUBLIN, Ireland and FORT WASHINGTON, Pa., June 02, 2021 GLOBE NEWSWIRE -- Nabriva Therapeutics plc NASDAQ: NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Dr. Mark Corrigan and Lisa Dalton have joined the Companys Board of Directors. In addition, after many years of service Dr. George Talbot has notified the company of his decision not to stand for re-election to the Board of Directors. Dr. Talbot is expected to continue his service on the Board of Directors until the conclusion of his term at the 2021 Annual General Meeting of Shareholders. 